Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistanceDaniele Cretella, Roberta Alfieri|Molecular Cancer|2014Cited by 67
Combined use of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) as target therapy in non-small cell lung cancer (NSCLC)Daniele Cretella|DSpaceUnipr (University of Parma)|2015Cited by 0